To determine the effect of orlistat on weight reduction and the long-term maintenance of this weight loss when associated with a continuous mildly reduced energy diet. DESIGN: A multicenter, 18-month, double-blind study conducted in 81 hospital centers. Patients were randomized to orlistat 120 mg or placebo three times daily in conjunction with a mildly reduced-energy diet maintained throughout the study. SUBJECTS: In total, 696 otherwise healthy, overweight patients aged 18-65 y (BMI Z28 kg/m 2 ) were randomized to treatment with orlistat (n ¼ 346) or placebo (n ¼ 350). MEASUREMENTS: Body weight, anthropometry, lipid and glycemic control parameters and blood pressure. RESULTS: After 18 months, patients treated with orlistat lost significantly more body weight compared with placebo (À6.570.8 vs À3.070.8%; P ¼ 0.0005). After 12 months, 32.9% of orlistat vs 24.5% of placebo patients lost Z10% of their initial weight (P ¼ 0.04). A significantly greater number of patients receiving orlistat treatment maintained this Z10% weight loss compared to those receiving placebo (28.1 vs 13.8%; Po0.0001). Compared with placebo, orlistat was associated with a greater decrease in fasting blood glucose (À0.8670.12 vs À0.2970.18 mmol/l; Po0.05) and LDL-cholesterol (À13.071.3 vs À7.071.3%; Po0.001). CONCLUSION: A clinically meaningful reduction in body weight and the maintenance of this weight loss is achievable with orlistat treatment and dietary restriction over a period of 18 months. This weight loss resulted in an improvement in risk factors for coronary heart disease.
Introduction
Overweight and obesity are associated with important risk factors for coronary heart disease such as type II diabetes, dyslipidemia and hypertension. 1, 2 The prevalence of obesity continues to grow at an ever-increasing rate and is now considered a chronic disease, presenting a major public health problem worldwide. 3, 4 A moderate weight loss of 5% or more significantly improves comorbid risk factors. Therefore, the achievement of this 5% weight loss is a goal for many treatment guidelines; 5 this weight loss should be maintained over the long term. 6 Conventional methods of treating obesity by diet and behavioral programs have often been unsuccessful, with very few patients able to achieve, and maintain, clinically beneficial weight loss. 7, 8 Orlistat (Xenical s ) is a nonsystemically acting gastrointestinal lipase inhibitor that reduces the absorption of dietary fat by approximately 30%. 9 Previous randomized, placebo-controlled studies in overweight and obese patients have consistently demonstrated that treatment with orlistat plus diet promotes significantly greater weight loss than diet alone. [10] [11] [12] In each of these 2-y studies, patients were prescribed a reduced-energy diet with a daily energy deficit of 600 kcal during the first year of treatment. During the second year, patients were prescribed a normal energy diet intended to promote weight maintenance rather than further weight loss. This aspect of the study design was intended to reflect a real-life situation in which patients become less compliant with a reduced-energy diet over time. Thus, most of the patients increased their food intake during the second year, and as a result, although weight was significantly reduced with orlistat compared with placebo, some regain of lost weight occurred during the second year. To date, no studies have assessed the effect of orlistat in combination with a continuous mildly reduced energy diet for longer than 1 y. The current study is the first in which weight loss and weight maintenance have been assessed with orlistat treatment for an 18-month period.
Methods

Patients
Men and women aged 18-65 y with a body mass index (BMI) of Z28 kg/m 2 were eligible for inclusion in the study.
Patients with serious eating disorders or type I or type II diabetes were excluded. Other exclusion criteria included: pregnant or lactating women; smoking Z1 pack of cigarettes per day or intention to stop smoking during the trial; previous surgical treatment for obesity; known or suspected substance abuse; significant thyroid, renal, hepatic, gastrointestinal or immune disorders, or concomitant use of medications that alter body weight, appetite or the absorption of food.
The study was conducted in compliance with the Declaration of Helsinki and in accordance with Good Clinical Practice Guidelines. The study protocol was approved by the ethical committee of Nantes, France. Written informed consent was obtained from each patient.
Study design
This double-blind, randomized, placebo-controlled, 18-month trial was conducted in 81 hospital centers in France. During screening, patient eligibility was assessed by interview and clinical examination. Eligible patients entered a 15-day placebo run-in period, on completion of which they were randomized to orlistat 120 mg or placebo three times daily for 18 months.
Food diaries were used to assess energy intake. Food and alcohol intake had to be recorded over consecutive 4-day periods that included a weekend. Initial energy intake was determined from these food diaries and a dietitian prescribed an individually tailored diet with a 20% energy reduction to begin at the start of the run-in period. Fat intake was limited to 30% of energy intake. Food diaries were repeated during the run-in period to ensure that patients had understood the dietary instructions and advice. Patients completed food diaries every 4 months during the study, before clinic visits at months 3, 7, 11, 15 and 18. At each of these visits, mean energy intake was assessed and adjusted if necessary. In patients who had lost weight since their previous visit, the same diet was maintained. However, the diet energy prescription was decreased by a further 10% (never below 1200 kcal/day) in patients with stable weight (70.5 kg since last visit) or weight gain.
Body weight, BMI and body fat (impedancemeter TANITA TBF 521, Tokyo) were assessed at clinic visits every month for the duration of the study. Other anthropometric parameters were measured every 2 months. Blood samples for fasting blood glucose (FBG), lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) and safety parameters were taken every 6 months.
Statistical analysis
Number of patients. It was planned to enroll 600 patients in this study in order to provide a statistical power of 80% with an a-level of 1% for the analysis of the primary criterion, and a statistical power of 80% with an a-level of 5% for the analysis of secondary criteria. A drop-out rate of 40% was assumed from previous data. 10 Analysis. Two intent-to-treat (ITT) analyses using data from all patients who had at least one post-baseline efficacy observation were performed: one with observed data using all the available data without replacing missing data (ITT 1 ), and one with last observation carried forward data (ITT 2 ). All reported data are observed values (ITT 1 ) from the beginning of weight management period (Day À15).
An additional analysis was conducted with per-protocol completer (PPC) patients using all the complete data during the 18 months of follow-up and without major protocol deviation defined by the Blind Review Committee.
The null hypothesis that the expected weight change after 18 months of treatment would be the same between treatment groups was tested using analysis of covariance (ANCOVA) adjusting for age, sex and body weight at Day À15. The absolute means and adjusted means (least-squares means (LSM)) were calculated with 99 or 95% confidence intervals.
An ANCOVA analysis of early treatment responders/ nonresponders and their characteristics was performed with the same model (early response effect was added in the model). Early treatment responders were defined as patients losing at least 5% of their baseline weight after 3 months of treatment.
Weight maintenance was assessed by comparing the 95% confidence interval of the LSM difference between groups in weight loss at 12 and 18 months. The proportion of patients with a weight loss of at least 10% of initial at 12 and 18 months were compared by a w 2 test. All results of quantitative criteria were presented as LSM7s.e.m. values. Changes from baseline in FBG, LDL-and HDL-cholesterol, triglycerides, systolic blood pressure (SBP) and diastolic blood pressure (DBP) to month 18 were assessed for those patients considered at risk at baseline: that is fasting glucose Z6.05 mmol/l, LDL cholesterol Z3.36 mmol/l, HDL cholesterol o0.90 mmol/l, triglycerides Z2.54 mmol/l, SBP Z140 mmHg and DBP Z90 mmHg.
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Analyses were performed with SAS Software (version 6.12, SAS Institute, Grègy sur Yerres, France).
Results
A total of 796 patients entered the study, of whom 696 completed the 15-day placebo run-in period and were randomized to double-blind treatment with orlistat (n ¼ 346) or placebo (n ¼ 350). There were 271 (38.9%) patients who prematurely withdrew from the study, 122 (35.3%) in the orlistat group and 149 (42.6%) in the placebo group (P ¼ 0.048). Main reasons for premature withdrawal during the double-blind treatment period included: withdrawal of informed consent (orlistat, n ¼ 38; placebo, n ¼ 53); treatment failure (n ¼ 21/36) and adverse events (n ¼ 23/11). In total, 14 patients were definitively lost to follow-up at the last study visit (n ¼ 4/10).
The characteristics of the patient population at randomization were similar in the two treatment groups with the exception of age, for which there was a statistically significant difference (P ¼ 0.04) between the groups (Table 1) . 
Food intake
Efficacy
Weight loss, expressed as the mean reduction in body weight throughout the 18 months of treatment, is shown in Figure 1 . After 12 months, mean weight loss from the start of the placebo run-in period was significantly greater with orlistat (À7.370.6 kg, 7.470.6%) than with placebo (À4.470.7 kg, À4.870.7%), with a LSM difference of À2.970.9 kg (À2.770.9%) (P ¼ 0.0014). Significantly greater weight loss with orlistat was maintained after 18 months: À6.470.8 kg (À6.570.8%) in the orlistat group compared to À2.770.8 kg (À3.070.8%) in the placebo group, and LSM difference increased to À3.771.1 kg (3.571.1%) (P ¼ 0.0005).
The mean weight regain between 12 and 18 months was lower in the orlistat group (+1.2 kg; 95% CI: 0.7; 1.7) compared to the placebo group (+1.4 kg; 95% CI: 0.9; 1.9), although this decrease was not statistically different. Weight The main efficacy results using observed (ITT 1 ), last observation carried forward (ITT 2 ), and PPC analyses are shown in Table 2 .
Risk factors
Total cholesterol levels were reduced by Z20% in 10.1% of orlistat patients compared with 2.6% of placebo patients, while LDL-cholesterol levels were reduced by Z20% in 19.9% of orlistat recipients and 6.6% of placebo-treated patients.
In patients initially at risk (see Table 3 ) FBG and LDLcholesterol were significantly improved in the orlistat group, whereas improvements in HDL-cholesterol, triglycerides and blood pressure were not significantly different between the two treatment groups.
Tolerability
The overall proportion of patients with at least one adverse event during the study was greater in the orlistat group than in the placebo group (86.1 vs 72.3%; Po0.001). This difference was because of the percentage of orlistat patients experiencing gastrointestinal events (63.3 vs 36.3%) suggesting fat intake was still excessive, although reduced from initial. These gastrointestinal events primarily occurred during the first month of therapy ( Figure 2 ) and were resolved spontaneously. A total of 24 (6.9%) orlistat-treated Weight loss and long-term maintenance with orlistat M Krempf et al patients and 12 (3.4%) placebo-treated patients withdrew from the study prematurely because of adverse events. Nine of these events, five in the orlistat group and four in the placebo group were serious adverse events leading to premature withdrawal from the study. Seven of them were deemed as doubtfully related to study drug by the investigators (orlistat: thrombotic thrombocytopenic purpura, anal abscess, pain hypocondrium and liver disorder; placebo: abdominal pain, breast cancer and ulcerative colitis). Nonclinically relevant changes in safety parameters occurred at a similar incidence in both the treatment groups.
Discussion
Despite greater understanding and more widespread recognition of the serious nature and consequences of overweight and obesity, weight loss and the long-term maintenance of weight loss remain difficult goals to achieve for most of patients. 7, 8 This randomized study is the first to demonstrate that weight loss and weight loss maintenance are achievable with orlistat combined with a continuous, mildly reducedenergy diet over a period of 18 months. Unlike previous orlistat trials, patients in the current study continued to follow the mildly reduced-energy diet for the entire 18-month treatment period. Weight reduction remained significantly higher in the orlistat group throughout the trial and the difference between treatments increased from month 12 to month 18. Weight loss achieved in the current study is lower than achieved after 1 year in previous 2-y studies of orlistat, 10, 11 which were largely conducted in centers staffed by specialists with considerable experience of treating obesity. However, this study was conducted in centers that did not highly specialize in the treatment of obesity, but in centers representative of general hospital medical practice in France. Furthermore, dietary adjustments in the current study were based upon food diaries kept by the patient. Numerous studies have documented that overweight patients frequently under-report their food intake. [13] [14] [15] Therefore, any dietary adjustments made in the current study based upon patient food diaries, probably underestimated the reduction in energy intake required. However, regular direct interviews with the dietician probably decreased this risk.
As would be expected, greater weight loss is observed in the PPC population compared to the last observation carried forward and observed data populations. Furthermore, the number of study completers was significantly higher in the orlistat treatment group compared to the placebo group. The completion rate of subjects in earlier orlistat trials over 1-2 y ranged from 43 to 65%. [10] [11] [12] The retention rates of 57 and 65% in the placebo and orlistat groups after 18 months of treatment in the present study are therefore in agreement with previous studies. Data were analyzed from the beginning of the diet prescription (À15 days) as most of the patients started to loss weight at this time point because they were strongly motivated in both groups. Moreover, the usual medical practice is to use the treatment prescription after diet treatment alone for variable length of time. Then, this method of analysis is close to a 'real life' situation. Approximately one-third of patients receiving orlistat treatment lost more than 10% of their body weight at 12 months compared to less than 25% of those patients in the placebo group. Interestingly, the majority of patients in the orlistat group maintained this weight loss at month 18, which suggests that orlistat could help to prevent weight regain.
The reduction in body fat mass observed in orlistat-treated patients was noticeably greater in comparison to overall weight loss. In both groups, fat-free mass slightly decreased but not significantly compared to baseline and less in the orlistat group. This observation emphasizes the importance of slow weight reduction in obese individuals.
In agreement with previous trials, 10-12 the weight reduction in the orlistat group was accompanied by beneficial Weight loss and long-term maintenance with orlistat M Krempf et al changes in lipid levels that were greater than could be expected by weight loss alone. Plasma total cholesterol and LDL-cholesterol concentrations were reduced in markedly more orlistat-treated patients than in placebo recipients. This treatment effect is probably a result of the partial inhibition of fat or cholesterol absorption from the gastrointestinal tract by orlistat. 16 Significant decreases of other risk factors are also observed in relation with the decrease of weight loss and abdominal circumference. However, these differences were not significant between the two groups for all parameters because of the small number of at risk patients included in this study.
With the exception of gastrointestinal events, the safety profile of orlistat was similar to that of placebo. Interestingly, the incidence of gastrointestinal events decreased markedly in the orlistat group after the first month of treatment, suggesting that patients learned to modify their fat intake in order to minimize these events. Although we did not observe any difference between treatment groups, it is likely that orlistat patients have decreased their fat intake. This continued low dietary fat intake is one strategy that has been identified as being positively associated with successful weight loss and weight maintenance. [17] [18] [19] [20] In conclusion, this study shows that treatment with orlistat, combined with a reduced-energy diet for 18 months, is more effective than dietary intervention alone in promoting meaningful weight loss and weight maintenance.
